Personalized treatment of early-stage breast cancer: Present concepts and future directions

Cancer Treatment Reviews

Volumn 36, Issue 8, 2010, Pages 584-594

  Harbeck, Nadia ^a   Salem, Marwa ^a   Nitz, Ulrike ^b   Gluz, Oleg ^b,c   Liedtke, Cornelia ^b,d  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b West German Study Group   (Germany)

^c Bethesda Hospital Wuppertal   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Breast cancer; Patient stratification; Personalized treatment; Predictive factor; Prognostic factor

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BSI 201; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DNA TOPOISOMERASE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; LAPATINIB; LETROZOLE; OLAPARIB; PACLITAXEL; PERTUZUMAB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG MECHANISM; GENE AMPLIFICATION; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; MEDICAL DECISION MAKING; ONCOGENE; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW;

ADULT; AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; FEMALE; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78349310879     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.04.007     Document Type: Review

References (95)

1. AGO Arbeitsgemeinschaft Gynäkologische Onkologie e. V., Germany; 2010. http://www.ago-online.de.
2. NCCN National Comprehensive Cancer Network, USA. http://www.nccn.org.
3. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8):1319-1329. [Epub 2009, June 17].
4. Perou C.M., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
5. Sorlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
6. Sorlie T., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423.
7. Wirapati P., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10(4):R65.
8. Parker J.S., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167.
9. Jänicke F., Prechtl A., Thomssen C., et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001, 93:913-920.
10. Look M.P., van Putten W.L., Duffy M.J., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94(2):116-128.
11. Harbeck N, Schmitt M, Meisner C, et al. Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer. 2009 ASCO annual meeting. J Clin Oncol 2009;27(15s) [Suppl; abstr 511].
12. Hayes D.F., Bast R.C., Desch C.E., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88(20):1456-1466.
13. Harris L, Fritsche H, Mennel R. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-312 [Epub 2007, October 22. Review].
14. Harbeck N., Kates R.E., Look M.P., et al. Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1. Cancer Res 2002, 62:4617-4622.
15. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826. [Epub 2004, December 10].
16. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24(23):3726-3734. [Epub 2006, May 23].
17. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65. [Epub 2009, December 10].
18. Goldstein L.J., O'Neill A., Sparano J.A., et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008, 26(25):4092-4099. [Epub 2008, August 4].
19. Paik S., Shak S., Tang G., et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol 2005, 23:510. [meeting abstracts].
20. Dowsett M., Cuzick J., Wales C., et al. Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Cancer Res 2009, 69:75S. [Abstr 53].
21. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional lecurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010 January 11 [Epub ahead of print].
22. Dowsett M, Cuzick J, Wale C. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010 March 8 [Epub ahead of print].
23. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23(29):7265-7277. [Epub 2005, September 6].
24. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
25. van de Vijver M.J., He Y.D., van 't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009.
26. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679.
27. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006, 24(11):1665-1671. [Epub 2006, February 27].
28. Buyse M., Loi S., van 't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98(17):1183-1192.
29. Desmedt C., Piette F., Loi S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13(11):3207-3214.
30. Mook S., Schmidt M.K., Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009, 116(2):295-302. [Epub 2008, July 27].
31. Mook S, Knauer M, Bueno-de-Mesquita JM, et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene mammaprint signature. Ann Surg Oncol 2010 January 22 [Epub ahead of print].
32. Straver M.E., Glas A.M., Hannemann J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119(3):551-558.
33. Knauer M., Knauer M., Mook S., Rutgers E.J., Bender R.A., Hauptmann M., et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2000, 120(3):655-661.
34. Kok M., Linn S.C., Van Laar R.K., et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2009, 113(2):275-283. [Epub 2008, March 4].
35. Zhang Y., Sieuwerts A.M., McGreevy M., et al. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 2009, 116(2):303-309. [Epub 2008, September 23].
36. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98(4):262-272.
37. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25(10):1239-1246.
38. Liedtke C., Hatzis C., Symmans W.F., et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009, 27(19):3185-3191. [Epub 2009, April 13].
39. Bertucci F, Le Doussal JM, Birnbaum D, et al. Prognostic value of the genomic grade index (GGi) as compared to centrally measured Ki-67 IHC and mitotic index in early breast cancer patients. J Clin Oncol 2009;27:15s [Abstr 11094].
40. Toussaint J., Sieuwerts A.M., Haibe-Kains B., et al. Improvement of the clinical applicability of the genomic grade index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 2009, 10:424.
41. Ein-Dor L., Zuk O., Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 2006, 103(15):5923-5928. [Epub 2006, April 3].
42. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355(6):560-569.
43. Haibe-Kains B., Desmedt C., Piette F., et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 2008, 9:394.
44. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-312 [Epub 2007, October 22. Review].
45. Cuzick J., Dowsett M., Wale C., et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score - results from TransATAC. Cancer Res 2009, 69(Suppl.).
46. Badve S., Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009, 62(1):6-12.
47. Paik S., Liu E.T. HER2 as a predictor of therapeutic response in breast cancer. Breast Dis 2000, 11:91-102.
48. Di Leo A., Chan S., Paesmans M., et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004, 86(3):197-206.
49. Gennari A., Sormani M.P., Pronzato P., et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100(1):14-20. [Epub 2007, December 25].
50. Di Leo A., Isola J., Piette F., et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Br Cancer Res Treat 2008, 214:107. [Abstr 705].
51. Bartlett J.M.S., Munro A., Dunn J.A., et al. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEAT adjuvant breast cancer trial. Breast Cancer Res Treat 2008, 107:20.
52. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: second interim efficacy analysis. Breast Cancer Res Treat 2006;100(Suppl. 1) [Abstr 52].
53. Knoop A.S., Knudsen H., Balslev E., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005, 23(30):7483-7490.
54. Ejlertsen B., Jensen M.B., Nielsen K.V., et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 2010, 28(6):984-990. [Epub 2009, December 28].
55. O'Malley F.P., Chia S., Tu D., et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009, 101(9):644-650. [Epub 2009, April 28].
56. Bartlett J.M., Munro A., Cameron D.A., et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 2008, 26(31):5027-5035. [Epub 2008, September 2].
57. Järvinen T.A., Liu E.T. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 2006, 6(7):579-602.
58. Bofin A.M., Ytterhus B., Hagmar B.M. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003, 14(6):314-319.
59. Sparano J.A., Goldstein L.J., Childs B.H., et al. Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 2009, 15(24):7693-7700. [Epub].
60. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
61. Goetz M.P., Kamal A., Ames M.M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008, 83(1):160-166. [Epub 2007, September 19].
62. Schroth W., Goetz M.P., Hamann U., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302(13):1429-1436.
63. Goetz M.P., Berry D.A., Klein T.E., et al. Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the International Tamoxifen Pharmacogenomics Consortium. Cancer Res 2009, 69(Suppl.):493s.
64. Ayers M., Symmans W.F., Stec J., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22(12):2284-2293.
65. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24(26):4236-4244. [Epub 2006, August 8].
66. Tabchy A., Symmans W.F., Valero V., et al. Evaluation of the predictive performance and regimen specificity of a 30-gene predictor of pathologic complete response in a prospective randomized neoadjuvant clinical trial for stage I-III breast cancer. Cancer Res 2009, 69(Suppl.):506s.
67. Albain K.S., Barlow W.E., Ravdin P.M., et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374(9707):2055-2063.
68. Esserman LJ, Perou C, Cheang M, et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). J Clin Oncol 2009;27:18s [Abstr LBA515].
69. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750.
70. Hugh J., Hanson J., Cheang M.C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27(8):1168-1176.
71. Penault-Llorca F., André F., Sagan C., et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27(17):2809-2815.
72. Martín M, Rodríguez-Lescure A, Ruiz A, et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2009; December 27 [Epub ahead of print].
73. Ellis M.J., Tao Y., Luo J., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 100(19):1380-1388.
74. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99(2):167-170.
75. Ellis M.J., Luo J., Tao Y., et al. Tumor Ki67 proliferation index within 4 weeks of initiating neoadjuvant endocrine therapy for early identification of non-responders. Cancer Res 2009, 69(Suppl.):504s.
76. Olson J.A., Budd G.T., Carey L.A., et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg 2009, 208(5):906-914. [Discussion 915-6].
77. Piccart M.J. International breast cancer research: launching an expedition to the moon. Cancer Res 2009, 69(Suppl.):485s.
78. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
79. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
80. von Minckwitz G., du Bois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27(12):1999-2006. [Epub 2009, March 16].
81. Blackwell K.L., Burstein H.J., Sledge G.W., et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 2009, 69(Suppl.):499s.
82. Baselga J., Cortes J., Fumoleau P., et al. Pertuzumab and trastuzumab: re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation. Cancer Res 2009, 69(Suppl.). [Abstr 5114].
83. O'Shaughnessy J., Osborne C., Pippen J., et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009, 27:18s.
84. Tutt A., Robson M., Garber J.E., et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27(18S). [CRA501].
85. Gray R., Bhattacharya S., Bowden C., et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009, 27(30):4966-4972. [Epub 2009, August 31].
86. Miles D.W., Chan A., Romieu G., et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (MBC). Cancer Res 2009, 69(24):495s.
87. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26(8):1275-1281. [Epub 2008, February 4].
88. Gluz O., Liedtke C., Gottschalk N., et al. Triple-negative breast cancer - current status and future directions. Ann Oncol 2009, 20(12):1913-1927. [Epub 2009, November 9].
89. Sparano JA, Goldestin LJ, Childs BH, et al. Genotypic characterization of phenotypically defined triple-negative breast cancer. J Clin Oncol 2009;27(15S):500 [ASCO meeting abstracts].
90. Liedtke C., Ruckert C., Goette M., et al. Secreted frizzled receptor protein 1 (sFRP-1) as both a potential novel biomarker of triple negative breast cancer (TNBC), and its sensitivity against taxane/anthracycline containing neoadjuvant chemotherapy. Cancer Res 2009, 69(Suppl.):722s.
91. Sweep C.G., Geurts-Moespot J., Grebenschikov N., et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998, 78(11):1434-1441.
92. ASCO American Society of Clinical Oncology. http://www.asco.org.
93. Annecke K., Schmitt M., Euler U., et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008, 45:31-45. [Review].
94. Sparano J.A., Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008, 26(5):721-728.
95. Cardoso F., van 't Veer L., Rutgers E., et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26(5):729-735.